Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02333162 · ClinicalTrials.gov registry record · Phase 1

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

A Phase 1 study of Recurrent Adult Acute Myeloid Leukemia and Previously Treated Myelodysplastic Syndrome, sponsored by University of Chicago.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT02333162: Recruiting Phase 1 study of Recurrent Adult Acute Myeloid Leukemia and Previously Treated Myelodysplastic Syndrome, sponsored by University of Chicago.

NCT02333162 is a Phase 1 study of Recurrent Adult Acute Myeloid Leukemia and Previously Treated Myelodysplastic Syndrome that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 30 participants, below the 53-participant average among 19 other Recurrent Adult Acute Myeloid Leukemia trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02333162, a Phase 1 study of Recurrent Adult Acute Myeloid Leukemia and Previously Treated Myelodysplastic Syndrome, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood (hematologic) that have returned after a period of improvement (relapsed) undergoing a second donor stem cell transplant. IMTMI is a type of radiation therapy to the bone marrow that may be less toxic and may also reduce the chances of cancer to return. Giving fludarabine phosphate, melphalan, and IMTMI before a donor stem cell transplant may help stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

Conditions Studied

Recurrent Adult Acute Myeloid Leukemia Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Hematologic Malignancy

Interventions

  • DRUG Melphalan
  • RADIATION Intensity-Modulated Radiation Therapy
  • DRUG Fludarabine Phosphate
  • PROCEDURE Allogeneic Hematopoietic Stem Cell Transplantation
  • RADIATION Total Marrow Irradiation

Study Locations (1)

Illinois

  • University of Chicago Comprehensive Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-12-05
Est. Completion 2028-12-01
Phase Phase 1
University of Chicago

796 total trials

What NCT02333162 shows while recruiting

NCT02333162 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 53-participant average among 19 other Recurrent Adult Acute Myeloid Leukemia trials with a reported enrollment target (43% lower).

The record links to 4 conditions, with Recurrent Adult Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.

NCT02333162 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT02333162 about?

NCT02333162 is a clinical study titled "Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant". This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood (hematologic) that have returned after a period of improvement (relapsed) ...

What is the current status of trial NCT02333162?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-12-05. Estimated completion is 2028-12-01.

What conditions does trial NCT02333162 study?

This clinical trial studies the following conditions: Recurrent Adult Acute Myeloid Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Hematologic Malignancy.

What interventions are being tested in trial NCT02333162?

The interventions under investigation include: Melphalan (DRUG), Intensity-Modulated Radiation Therapy (RADIATION), Fludarabine Phosphate (DRUG), Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE), Total Marrow Irradiation (RADIATION).

Who is sponsoring clinical trial NCT02333162?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02333162 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Adult Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02333162's enrollment target sits among peer trials

30 12th of 19 higher than 7 of 19 other Recurrent Adult Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Recurrent Adult Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT02333162

Source: ClinicalTrials.gov NCT02333162, the US trial registry maintained by the National Library of Medicine. NCT02333162 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.